|
1
|
Keating MJ, O'Brien S, Albitar M, Lerner
S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D,
et al: Early results of a chemoimmunotherapy regimen of
fludarabine, cyclophos-phamide and rituximab as initial therapy for
chronic lymphocytic leukemia. J Clin Oncol. 23:4079–4088. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Badoux XC, Keating MJ, Wang X, O'Brien SM,
Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H
and Wierda WG: Fludarabine, cyclophosphamide and rituximab
chemoimmunotherapy is highly effective treatment for relapsed
patients with CLL. Blood. 117:3016–3024. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li PP and Wang X: Role of signaling
pathways and miRNAs in chronic lymphocytic leukemia. Chin Med J.
126:4175–4182. 2013.PubMed/NCBI
|
|
4
|
Chen J and McMillan NA: Molecular basis of
pathogenesis, prognosis and therapy in chronic lymphocytic
leukaemia. Cancer Biol Ther. 7:174–179. 2008. View Article : Google Scholar
|
|
5
|
Ten Hacken E and Burger JA:
Microenvironment dependency in chronic lymphocytic leukemia: The
basis for new targeted therapies. Pharmacol Ther. 144:338–348.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shain KH and Tao J: The B-cell receptor
orchestrates environment-mediated lymphoma survival and drug
resistance in B-cell malignancies. Oncogene. 33:4107–4113. 2014.
View Article : Google Scholar
|
|
7
|
Robak T and Robak P: BCR signaling in
chronic lymphocytic leukemia and related inhibitors currently in
clinical studies. Int Rev Immunol. 32:358–376. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Farooqui MZ, Valdez J, Martyr S, Aue G,
Saba N, Niemann CU, Herman SE, Tian X, Marti G, Soto S, et al:
Ibrutinib for previously untreated and relapsed or refractory
chronic lymphocytic leukaemia with TP53 aberrations: A phase 2,
single-arm trial. Lancet Oncol. 16:169–176. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zelenetz AD, Gordon LI, Wierda WG,
Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman
MS, Fayad LE, et al National comprehension cancer network: Chronic
lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J
Natl Compr Canc Netw. 13:326–362. 2015.PubMed/NCBI
|
|
10
|
Alinari L, Quinion C and Blum KA: Bruton's
tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas. Clin
Pharmacol Ther. 97:469–477. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Da Roit F, Engelberts PJ, Taylor RP, Breij
EC, Gritti G, Rambaldi A, Introna M, Parren PW, Beurskens FJ and
Golay J: Ibrutinib interferes with the cell-mediated anti-tumor
activities of therapeutic CD20 antibodies: Implications for
combination therapy. Haematologica. 100:77–86. 2015. View Article : Google Scholar
|
|
12
|
Herman SE, Mustafa RZ, Gyamfi JA,
Pittaluga S, Chang S, Chang B, Farooqui M and Wiestner A: Ibrutinib
inhibits BCR and NF-kB signaling and reduces tumor proliferation in
tissue-resident cells of patients with CLL. Blood. 123:3286–3295.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
James RG, Biechele TL, Conrad WH, Camp ND,
Fass DM, Major MB, Sommer K, Yi X, Roberts BS, Cleary MA, et al:
Bruton's tyrosine kinase revealed as a negative regulator of Wnt-
beta- catenin signaling. Sci Signal. 2:2009. View Article : Google Scholar
|
|
14
|
Yang Y, Shi J, Gu Z, Salama ME, Das S,
Wendlandt E, Xu H, Huang J, Tao Y, Hao M, et al: Bruton tyrosine
kinase is a therapeutic target in stem-like cells from multiple
myeloma. Cancer Res. 75:594–604. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gutierrez A Jr, Tschumper RC, Wu X,
Shanafelt TD, Eckel-Passow J, Huddleston PM III, Slager SL, Kay NE
and Jelinek DF: LEF-1 is a prosurvival factor in chronic
lymphocytic leukemia and is expressed in the preleukemic state of
monoclonal B-cell lymphocytosis. Blood. 116:2975–2983. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ge X, Lv X, Feng L, Liu X, Gao J, Chen N
and Wang X: Metadherin contributes to the pathogenesis of diffuse
large B-cell lymphoma. PLoS One. 7:e394492012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
18
|
Herman SE, Gordon AL, Hertlein E,
Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy
JJ, et al: Bruton tyrosine kinase represents a promising
therapeutic target for treatment of chronic lymphocytic leukemia
and is effectively targeted by PCI-32765. Blood. 117:6287–6296.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li P, Feng LL, Chen N, Ge XL, Lv X, Lu K,
Ding M, Yuan D and Wang X: Metadherin contributes to the
pathogenesis of chronic lymphocytic leukemia partially through
Wnt/β-catenin pathway. Med Oncol. 32:4792015. View Article : Google Scholar
|
|
20
|
Maddocks K, Christian B, Jaglowski S,
Flynn J, Jones JA, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC
and Blum KA: A phase 1/1b study of rituximab, bendamustine and
ibrutinib in patients with untreated and relapsed/refractory
non-Hodgkin lymphoma. Blood. 125:242–248. 2015. View Article : Google Scholar
|
|
21
|
Hallek M, Kay NE, Osterborg A, Chanan-Khan
AA, Mahler M, Salman M, Wan Y, Sun S, Zhuang SH and Howes A: The
helios trial protocol: A Phase III study of ibrutinib in
combination with bendamustine and rituximab in relapsed/refractory
chronic lymphocytic leukemia. Future Oncol. 11:51–59. 2015.
View Article : Google Scholar
|
|
22
|
Cheng S, Guo A, Lu P, Ma J, Coleman M and
Wang YL: Functional characterization of BTK (C481S) mutation that
confers ibrutinib resistance: Exploration of alternative kinase
inhibitors. Leukemia. 29:885–900. 2015. View Article : Google Scholar
|
|
23
|
Zelenetz AD, Gordon LI, Wierda WG,
Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman
MS, Fayad LE, et al National comprehensive cancer network:
Non-Hodgkin's lymphomas, version 4.2014. J Natl Compr Canc Netw.
12:1282–1303. 2014.PubMed/NCBI
|
|
24
|
Woyach JA, Furman RR, Liu TM, Ozer HG,
Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, et
al: Resistance mechanisms for the bruton's tyrosine kinase
inhibitor ibrutinib. N Engl J Med. 370:2286–2294. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Burger JA, Keating MJ, Wierda WG, Hartmann
E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli
A, Cardenas-Turanzas M, et al: Safety and activity of ibrutinib
plus rituximab for patients with high-risk chronic lymphocytic
leukaemia: A single-arm, phase 2 study. Lancet Oncol. 15:1090–1099.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Logan CY and Nusse R: The Wnt signaling
pathway in development and disease. Annu Rev Cell Dev Biol.
20:781–810. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nusse R: Wnt signaling in disease and in
development. Cell Res. 15:28–32. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gough NR: Focus issue: Wnt and β- catenin
signaling in development and disease. Sci Signal. 5:2012.
View Article : Google Scholar
|
|
29
|
Gordon MD and Nusse R: Wnt signaling:
Multiple pathways, multiple receptors and multiple transcription
factors. J Biol Chem. 281:22429–22433. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Memarian A, Hojjat-Farsangi M,
Asgarian-Omran H, Younesi V, Jeddi-Tehrani M, Sharifian RA,
Khoshnoodi J, Razavi SM, Rabbani H and Shokri F: Variation in Wnt
genes expression in different subtypes of chronic lymphocytic
leukemia. Leuk Lymphoma. 50:2061–2070. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M,
Leoni LM, Kipps TJ, Corr M and Carson DA: Activation of the Wnt
signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad
Sci USA. 101:3118–3123. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gandhirajan RK, Staib PA, Minke K, Gehrke
I, Plickert G, Schlösser A, Schmitt EK, Hallek M and Kreuzer KA:
Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling
induces apoptosis in chronic lymphocytic leukemia cells in vitro
and in vivo. Neoplasia. 12:326–335. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gandhirajan RK, Poll-Wolbeck SJ, Gehrke I
and Kreuzer KA: Wnt/β-catenin/LEF-1 signaling in chronic
lymphocytic leukemia (CLL): A target for current and potential
therapeutic options. Curr Cancer Drug Targets. 10:716–727. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lu D, Liu JX, Endo T, Zhou H, Yao S,
Willert K, Schmidt-Wolf IG, Kipps TJ and Carson DA: Ethacrynic acid
exhibits selective toxicity to chronic lymphocytic leukemia cells
by inhibition of the Wnt/beta-catenin pathway. PLoS One.
4:e82942009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lu D, Choi MY, Yu J, Castro JE, Kipps TJ
and Carson DA: Salinomycin inhibits Wnt signaling and selectively
induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl
Acad Sci USA. 108:13253–13257. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li P, Yao QM, Zhou H, Feng LL, Ge XL, Lv
X, Chen N, Lu K and Wang X: Metadherin contribute to BCR signaling
in chronic lymphocytic leukemia. Int J Clin Exp Pathol.
7:1588–1594. 2014.PubMed/NCBI
|
